IMVT

Immunovant, Inc.

28.40 USD
-0.01 (-0.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immunovant, Inc. stock is up 8.44% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
05 Jul 18:11 17 Jan, 2025 35.00 CALL 208 2560
05 Jul 19:39 17 Jan, 2025 35.00 CALL 162 2560
08 Jul 19:30 17 Jan, 2025 35.00 CALL 100 3159
09 Jul 13:51 17 Jan, 2025 35.00 CALL 83 3461
11 Jul 17:27 19 Jul, 2024 25.00 CALL 160 1131
15 Jul 14:15 17 Jan, 2025 40.00 CALL 99 2308
15 Jul 14:16 17 Jan, 2025 40.00 CALL 100 2308
15 Jul 14:17 17 Jan, 2025 40.00 CALL 100 2308
15 Jul 14:18 17 Jan, 2025 40.00 CALL 100 2308
15 Jul 14:19 17 Jan, 2025 40.00 CALL 100 2308

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.